

1 EEG Power Spectral Slope differs by ADHD status and stimulant medication exposure in early
2 childhood.

3 **Running Title:** EEG Power Spectral Slope in Early Childhood ADHD

4
5 Madeline M. Robertson¹, Sarah Furlong¹, Bradley Voytek², Thomas Donoghue²,
6 Charlotte A. Boettiger¹, and Margaret A. Sheridan¹

7 ¹Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill,
8 Chapel Hill, NC, USA

9 ²Department of Cognitive Science, University of California San Diego, San Diego, CA, USA

10 **Corresponding Author:** Margaret A. Sheridan
11 Department of Psychology and Neuroscience
12 University of North Carolina at Chapel Hill
13 CB#3270, 235 E. Cameron Avenue,
14 Chapel Hill, NC, 27514.
15 Email: sheridan.margaret@unc.edu
16

17 **Number of figures:** 6

18 **Number of tables:** 3

19 **Abstract:** 237 words

20 **Introduction:** 1051 words

21 **Discussion:** 1209 words

22 **Author Contributions:** Conception and design of research: MMR, CAB, MAS
23 Performed experiments: MAS
24 Analyzed data: MMR, SF
25 Interpreted results of experiments: MMR, BV, TD, CAB, MAS
26 Drafted manuscript and prepared figures: MMR
27 Edited manuscript: MMR, SF, BV, CAB, MAS
28 Approved final version of manuscript: MMR, SF, BV, TD, CAB,
29 MAS
30

31 **Key Words:** Attention-deficit/hyperactivity disorder; electroencephalography; power spectrum;
32 spectral slope; theta/beta ratio
33
34

35
36
37
38
39
40
41
42
43

Acknowledgements: This work was supported by the National Institute of Drug Abuse T32DA007244 (MMR) and R03-DA037405 (MAS); Alfred P. Sloan Foundation FG-2015-66057 (BV), Whitehall Foundation 2017-12-73 (BV), National Science Foundation BCS-1736028 (BV), National Institute on Alcohol Abuse and Alcoholism P60AA011605 (CAB), and National Institute of Nursing Research R01NR017221 (CAB), and the National Institutes of Mental Health K01-MH092555 (MAS). The authors thank Julio Dominguez and Michelle Kim for their insights and technical assistance. The authors declare no conflicts of interests.

44 **ABSTRACT**

45 Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental
46 disorder characterized by hyperactivity/impulsivity and inattentiveness. Efforts towards the
47 development of a biologically based diagnostic test have identified differences in the EEG power
48 spectrum, most consistently reported is an increased ratio of theta to beta power during resting-
49 state in those with the disorder, compared to controls. Current approaches calculate theta/beta
50 ratio using fixed frequency bands, but the observed differences may be confounded by other
51 relevant features of the power spectrum, including shifts in peak oscillation frequency, and
52 altered slope or offset of the aperiodic 1/f-like component of the power spectrum. In the present
53 study, we quantify the spectral slope and offset, peak alpha frequency, and band-limited and
54 band-ratio oscillatory power in the resting-state EEG of 3-7-year-old children with and without
55 ADHD. We found that medication-naïve children with ADHD had higher alpha power, greater
56 offsets, and steeper slopes compared to typically developing children. Children with ADHD who
57 were treated with stimulants had comparable slopes and offsets to the typically developing group
58 despite a 24-hour medication washout period. We further show that spectral slope correlates with
59 traditional measures of theta/beta ratio, suggesting the utility of slope as a neural marker over
60 and above traditional approaches. Taken with past research demonstrating that spectral slope is
61 associated with executive functioning and excitatory/inhibitory balance, these results suggest that
62 altered slope of the power spectrum may reflect pathology in ADHD.

63

64

65 **NEW & NOTEWORTHY.** This manuscript highlights the clinical utility of comprehensively
66 quantifying features of the EEG power spectrum. Using this approach, we identify for the first

67 time, differences in the aperiodic components of the EEG power spectrum in children with
68 ADHD, and provide evidence that spectral slope is a robust indicator of an increase in low relative
69 to high frequency power in ADHD.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 INTRODUCTION

89 Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental
90 disorder characterized by hyperactivity/impulsivity and inattentiveness. Children with ADHD are
91 more likely to exhibit poor educational outcomes (Loe and Feldman 2007), social-emotional
92 problems (Wehmeier et al. 2010) and substance use disorders (Wilens et al. 2011) that persist
93 into adulthood. Recent estimates place the worldwide prevalence of ADHD between 5.3-7.2%
94 (Polanczyk et al. 2007; Polanczyk et al. 2014; Thomas et al. 2015), though the rate of diagnosis
95 in the United States is higher, estimated at 7.7% for 4-11-year-olds, and 13.5% for 12-17-year-
96 olds (Xu et al. 2018). In addition to varying by age, diagnostic rates vary by gender, race, and
97 ethnicity. Specifically, females and Hispanic and African American children are diagnosed at
98 lower rates than Caucasian males (Polanczyk et al. 2014; Visser et al. 2014; Xu et al. 2018).
99 These inconsistencies appear to reflect disproportionate diagnosis rather than true differences in
100 prevalence between these populations (Bruchmuller et al. 2012; Merten et al. 2017).

101 One potential solution to the misdiagnosis of ADHD is a sensitive and specific
102 biologically based diagnostic test. Towards this, a large body of research has sought to identify
103 biomarkers of ADHD diagnosis and symptomology. Many of these efforts have focused on
104 resting state electroencephalography (EEG), due in part to the clinical accessibility and cost-
105 effectiveness of EEG. One of the more consistent findings differentiating ADHD from controls
106 comes from analysis of the EEG power spectrum. Children with ADHD tend to have relatively
107 greater power in the low frequency theta range along with relatively reduced power in the high
108 frequency beta range compared to typically developing children; this is referred to as the
109 theta/beta ratio and has commonly been proposed as a potential biomarker of ADHD (Barry et al.
110 2003; Loo and Makeig 2012; Monastra et al. 2001; Monastra et al. 1999; Snyder and Hall 2006).

111 In addition to elevated theta/beta ratio in ADHD, a recent study found reductions in theta/beta
112 ratio following treatment with methylphenidate, a common stimulant used to treat ADHD, which
113 persisted after a 24-hour medication washout (Isiten et al. 2017). This finding is consistent with
114 reports that treatment with stimulant medications ameliorates EEG and cortical structure
115 abnormalities in ADHD patients (Clarke et al. 2017; Clarke et al. 2003; Nakao et al. 2011; Shaw
116 et al. 2009; reviewed in Spencer et al. 2013).

117 Despite the fact that reduced theta/beta ratio is one of the more consistently observed
118 differences between ADHD and control subjects, its diagnostic utility is low due to failed
119 replications and diminishing effect sizes over time (Arns et al. 2013; Loo and Makeig 2012; Saad
120 et al. 2018). One potential explanation for this variability is that current approaches calculate
121 theta/beta ratio using fixed frequency bands, defining theta as EEG power between 4-8 Hz, and
122 beta as EEG power between 13-21 Hz (Monastra et al. 1999). Importantly, observed group
123 differences in theta/beta ratio could be explained not just by differences in narrowband
124 oscillatory power, but by other dynamic and physiologically relevant features of the power
125 spectrum, including a shift in peak oscillation frequencies, and altered slope or offset of the
126 aperiodic, 1/f-like, component of the power spectrum (Gao 2016; Haller et al. 2018).

127 Differences in oscillatory power across conditions are the most extensively studied
128 feature of the EEG power spectrum (Fig.1A). Differences in oscillatory power have been linked
129 both to disease states, as well as to a wide variety of cognitive processes (Basar et al. 1999; 2001;
130 Klimesch 1999; Makeig et al. 2002). For example, studies have linked task-related increases in
131 theta oscillations with enhanced cognitive performance, including working memory (Hsieh and
132 Ranganath 2014), and attention (Makeig et al. 2002). Conversely, chronic elevations in theta
133 power have been associated with cognitive impairment observed in old age (reviewed in

134 Klimesch 1999), and in disease states, including ADHD (Barry et al. 2003) and Alzheimer's
135 disease (Fernandez et al. 2002). In addition to differences in oscillatory power, the peak
136 frequency within these frequency bands can also vary (Fig. 1B). For example, the location of the
137 peak frequency within the alpha band increases with age during childhood (Epstein 1980;
138 Marshall et al. 2002), peaks in early adulthood, and then decreases during older adulthood
139 (Aurlien et al. 2004) at which point a lower peak frequency is associated with diminished
140 executive function (Grandy et al. 2013). Furthermore, oscillatory peaks within defined
141 frequency bands exist atop an aperiodic signal reflecting diminished power with increasing
142 frequency, which varies in terms of slope and offset (He 2014). The slope of the aperiodic signal,
143 or rate of decline in power with increasing frequency (Fig. 1C) fluctuates with cognitive state
144 (Podvalny et al. 2015), and is associated with aging, executive function (Voytek et al. 2015), and
145 synaptic excitatory/inhibitory balance (Gao et al. 2017). In contrast, the offset, or broadband
146 power of the signal (Fig. 1D), may reflect the firing rate of neuronal populations (Manning et al.
147 2009). Thus, typical EEG approaches that do not fully characterize the power spectrum may
148 conflate differences in the ratio of low frequency to high frequency oscillations with shifts in
149 peak frequencies, power spectral slope and/or offset. For example, increased power in a low
150 frequency band (theta) relative to a higher frequency band (beta) may be better assessed by
151 measuring the slope of the aperiodic signal, as this would implicitly measure the relative power
152 in high and low frequencies without relying on arbitrarily defined frequency bands.

153 In the present study, we took such a comprehensive approach, and compared the slope,
154 offset, peak alpha frequency, and band-limited and band-ratio relative power of the resting-state
155 EEG signal in a sample of 3-7-year-old, medication-naïve children with ADHD ($n=50$), and age
156 and gender matched typically-developing controls (TD; $n=50$). In addition, we compared these

157 aspects of the EEG power spectra in 3-7-year-old children with ADHD and a history of stimulant
158 treatment ($n=26$), to age and gender matched medication-naïve children with ADHD ($n=26$) and
159 typically developing controls ($n=26$). Given previous literature documenting theta/beta ratio
160 differences associated with childhood ADHD and suggesting normalization of the EEG power
161 spectra with stimulant treatment, we hypothesized that medication-naïve children with ADHD
162 would have steeper slopes compared to typically developing controls, and that treatment with
163 stimulants would flatten the EEG power spectral slope. We further hypothesized that slope
164 estimates would correlate with traditional estimates of theta/beta ratio, reflecting the utility of
165 measuring EEG power spectral slope as a robust indicator of relative low to high frequency
166 power in children with ADHD.

167

168 **MATERIALS AND METHODS**

169 *Participants*

170 A total of 127 children (26.8% female) between the ages of 3 years 0 months and 7 years 4
171 months ($M=5$ years 9 months, $SD=1$ year 2 months) participated in the present study from a
172 sample of children ($N=197$) in a longitudinal study evaluating stability of ADHD diagnosis.
173 Participants were recruited from schools, community events, and databases consisting of children
174 seen for ADHD at Boston Children's Hospital, or whose families expressed interest in
175 participating in research within the Labs of Cognitive Neuroscience at Boston Children's
176 Hospital. From the larger sample, we excluded participants due to parent report of genetic
177 abnormalities ($n=1$), prenatal substance exposure ($n=2$), parent report of autism spectrum
178 disorder confirmed during study assessments ($n=1$), parental language barriers ($n=1$), refusal to
179 participate after time of consent ($n=1$), active use of a non-stimulant psychotropic medication
180 ($n=19$), or insufficient artifact-free EEG data as determined by a trained experimenter ($n=18$; 11

181 ADHD, 7 Control). Of the remaining participants, 76 met criteria for ADHD and 78 were
182 classified as typically developing controls. Of those who met criteria for ADHD, 50 were
183 medication naïve (ADHD-), and 26 were actively treated with stimulant medications but
184 underwent a 24-hour medication washout prior to study procedures (ADHD+). The 24-hour
185 wash-out period was determined based on parent-report, and is the standard washout period used
186 for stimulants given their short half-life (Cole et al. 2008; Isiten et al. 2017; Valera et al. 2010;
187 Wigal et al. 2007). A group of 50 typically developing (TD) participants was selected to match
188 the ADHD- group regarding both age and gender, and a subset of participants from the TD and
189 ADHD- groups were selected to age and gender match the group of 26 ADHD+ participants.
190 See Table 1 for demographics. All study procedures complied with the Helsinki Declaration and
191 were approved by the Institutional Review Board at Boston Children’s Hospital. All child
192 participants provided verbal assent, and their primary caregivers provided written informed
193 consent.

194

195 *ADHD Diagnosis*

196 ADHD diagnosis was determined during the study visit using the Diagnostic Structured
197 Interview Schedule– young child version (DISC-IV; Shaffer et al. 2000) . In some cases,
198 additional information was obtained from the Achenbach child behavior checklist (CBCL 1.5-5
199 or 6-18 depending on age; Achenbach 1994), and the Swanson Nolan and Pelham Checklist
200 (SNAP-IV; Swanson 2011). Children included in the ADHD group either met diagnostic criteria
201 on the DISC-IV (n=64), or received a subthreshold score on the DISC-IV (n=8) but met clinical
202 thresholds on either the CBCL (ADHD subscale t-score ≥ 70 , n= 3), the SNAP-IV (caregiver
203 endorsed 6/9 inattention or hyperactivity symptoms, n=4), or both (n=1). In addition, two

204 participants met neither clinical nor subclinical threshold on the DISC-IV but met clinical
205 threshold on the SNAP-IV (n=1) or both the SNAP-IV and the CBCL (n=1). Further, due to
206 technical difficulties, two participants did not have DISC-IV scores, but met criteria on both the
207 CBCL and the SNAP-IV (n= 2).

208 Teacher report of ADHD symptoms was assessed using either the Teacher Report Form
209 of the CBCL (TRF; Achenbach 1994) or the Conners-3 Teacher Rating Scale (Conners 2001) in
210 48% of participants (N=61) due to complications in data collection. There was no difference in
211 ADHD symptoms between participants with and without teacher report on either the DISC,
212 CBCL, or SNAP-IV ($p's > 0.40$). ADHD symptoms by group membership for each of the
213 measures is shown in Table 2 for the full ADHD- and TD samples, and Table 3 for the ADHD+
214 sample and the age- and gender- matched TD and ADHD- subsamples.

215

216 *EEG Acquisition*

217 EEG data was obtained during eyes open and eyes closed resting state conditions for a
218 total of 7 minutes. During the recording period, the participants cycled through 30 seconds of
219 eyes open data collection in which the child directed their attention toward a cartoon image of
220 open eyes; a 15 second break in which a research assistant encouraged the child's continued
221 compliance; and 30 seconds of eyes closed data collection in which the child was instructed to sit
222 calmly with their eyes closed. This process was repeated seven times. While this is a non-
223 standard procedure for collecting resting state EEG data, it was designed to maximize the
224 amount of artifact-free data given the young age of the children participating in the study and
225 similar procedures have been used elsewhere with children in this age range (Vuga et al. 2008).
226 Even within this specially designed procedure, young children were unable to follow the

227 direction to sit calmly with their eyes closed. Specifically during the eyes closed section, children
228 tended to squeeze their eyes shut, squint, or open and close their eyes repeatedly to observe the
229 room. This resulted in an excessive amount of muscle and movement artifact for the eyes closed
230 segments, thus these were excluded from further analysis and only eyes open segments were
231 used.

232 EEG data was recorded with a 128-channel HydroCel Geodesic Sensor Net System
233 (Electrical Geodesics Inc., Eugene, OR) with a NetAmps 200 Amplifier and NetStation software
234 at an effective sampling rate of 250 Hz. Electrodes were maintained such that at least 90% of the
235 128 electrodes had impedances below 50 k Ω prior to initiating the resting state recording.

236

237 *EEG Pre-Processing*

238 Data were preprocessed using NetStation. Recordings were high-pass filtered to 0.1 Hz
239 and low-pass filtered to 100 Hz. Then, data was segmented into the eyes open and eyes closed
240 conditions. The best 2-4 eyes open segments were selected, and these were concatenated to form
241 a 1-2-minute block of eyes open resting state data. While data length did not differ between the
242 ADHD+ group and the age and gender-matched TD and ADHD- subgroups ($F_{(2,75)}=0.833$,
243 $p=0.439$), there was a trend level group difference in length of data between the full ADHD-
244 group (M=111.97 seconds, SD=18.28) and TD group (M=117.99 seconds, SD=11.91; $t_{(84.26)} =$
245 6.02, $p=0.054$). As a result, we controlled for data length in all analyses.

246 After segmenting and concatenating the data, any electrodes with artifacts outside of a
247 ± 80 mV range were removed, and were replaced with data interpolated from the remaining
248 electrodes. Eye and other radial electrodes were removed from all analyses. Finally, all channels

249 were re-referenced to the average reference (Liu et al. 2015), and exported to MATLAB
250 (MathWorks Inc., Natick MA) for further processing.

251 We identified and removed eye-blinks and muscle movements using Independent
252 Components Analysis (ICA) in EEGLAB (Delorme and Makeig 2004). Prior to ICA, recordings
253 were high-passed filtered to 1 Hz due to evidence that this improves artifact detection (Winkler
254 et al. 2015). Electrode locations from the 128-channel montage were mapped and reduced to the
255 10-10 International System (Luu and Ferree 2005) to account for highly correlated signal from
256 nearby electrodes (Onton and Makeig 2006). Then, the ICA decomposition was calculated in
257 EEGLAB and we used the MARA EEGLAB plug-in (Winkler et al. 2014; Winkler et al. 2011).
258 MARA is a supervised machine-learning algorithm that has been pre-trained to identify and label
259 independent components of the EEG signal as artifact or neural activity based on six features
260 described in Winkler et al. (2014). Of the 71 components derived from ICA, only the first 12
261 accounted for more than 1% of the variance each. As such, a trained experimenter (SF) visually
262 inspected these first 12 components to verify MARA's artifact classification. In the rare
263 instances when it differed from MARA's classification, the experimenter's classification by
264 visual inspection was used. The remaining 59 components were classified solely based on
265 MARA's calculated probabilities, with those assigned a probability greater than 0.50 were
266 marked as artifact, and their time series were subtracted from the overall signal creating a
267 cleaned signal that is used for further analysis.

268

269 *Data Analysis*

270 We first estimated power spectral density (PSD) using Welch's method with a Hamming
271 window length of 1 second, and 50% overlap (Gao et al. 2017). To independently examine the

272 four components of the electrophysiological power spectrum (Fig. 1. A-D), we used the Fitting
273 Oscillations & One Over f (FOOOF) toolbox to calculate slope and offset (Haller et al. 2018),
274 and visually detected each individual's peak alpha frequency (PAF), which was then used to
275 estimate individualized narrow-band power (Doppelmayr et al. 1998). We assessed each of these
276 parameters at 12 midline electrodes across the frontal, central, parietal and occipital regions
277 (FCZ, FZ, F3, F4, C3, C4, CZ, P3, P4, PZ, O1, O2).

278

279 *Individualized Peak Alpha Frequency.* We determined PAF through visual inspection of
280 the plot of the power spectrum. PAF detection was performed within the predefined alpha band
281 of 5.5–13 Hz (Klimesch 1999; Marshall et al. 2002), and defined as the average point of highest
282 amplitude within that range for the 12 channels tested. Two researchers (MR and MK)
283 independently identified the peak within the alpha range to the nearest 0.25 Hz with 83%
284 concordance. In those instances where the researchers differed in their classifications, the PAF
285 was re-evaluated to ensure accurate selection. Cases of discordance were due to either split
286 peaks, or minimal deviation from the aperiodic background scaling. If, upon re-evaluation, the
287 researchers could not agree upon a dominant peak, split peaks were averaged together to estimate
288 PAF, whereas those with minimal deviation from background scaling were regarded as having
289 no PAF and were excluded from PAF analysis. Of 100 participants, 91 had a clear alpha peak. Of
290 the nine individuals without an alpha peak, four were in the TD group and five were in the
291 ADHD- group. Those with and without alpha peaks did not differ in regards to group
292 ($t_{(98)}=0.346$, $p=0.730$), age ($t_{(98)}=0.534$, $p=0.595$), or data length ($t_{(98)}=1.090$, $p=0.278$), but there
293 was a trending difference in gender ($t_{(98)}=1.947$, $p=0.054$) with females being more likely to not
294 have an alpha peak.

295

296 *Frequency Band Analysis.* In order to account for observations that frequency
297 bandwidths vary based on PAF, individualized frequency bands were calculated as a percentage
298 of the PAF as follows: theta [$\text{PAF} \times 0.4 - \text{PAF} \times 0.6$] and alpha [$\text{PAF} \times 0.6 - \text{PAF} \times 1.2$]
299 (Doppelmayr et al. 1998). Previous work has shown that this approach better accounts for
300 variations in bandwidth that occur as a function of PAF (Doppelmayr et al. 1998), which in turn
301 varies with age (Aurlien et al. 2004; Epstein 1980; Marshall et al. 2002). For the nine
302 participants with no clear alpha peak, we instead calculated individualized frequency bands using
303 the average PAF for the ADHD- and TD groups, which were 8.43 and 8.84, respectively. To
304 account for differences in the amplitude of the EEG signal due to noise including skull thickness
305 and electrode impedance, we calculated relative power by dividing the power within each band
306 by the total power (Gasser et al. 1982; Kappenman and Luck 2010). To allow for direct
307 comparison with existing literature, theta/beta ratio was calculated using standard methods
308 described in Monastra et al. (1999), which divides theta band power between 4-8 Hz by beta
309 band power between 13-21 Hz.

310

311 *Slope and Offset.* We used the FOOOF toolbox (Haller et al. 2018) to calculate the slope
312 (Fig. 1C) and offset (Fig. 1D) of the PSD between 4 and 50 Hz. Briefly, we first modeled the
313 aperiodic slope, then found the oscillatory peaks and fit them with Gaussians. We then subtracted
314 the Gaussians iteratively until all peaks were removed. We then refit the aperiodic slope of the
315 power spectrum with the peaks removed using an exponential function in semi-log power space.
316 This procedure provides an estimate for each EEG channel of two key aperiodic features of the
317 power spectrum: slope and offset.

318

319 *Statistics.* Data were analyzed using IBM SPSS Statistics version 25, and SAS version
320 9.4. To examine electrophysiological differences related to ADHD diagnoses, we conducted a
321 single factor analysis of covariance (ANCOVA). To evaluate the relationship between slope and
322 theta/beta ratio, we conducted a partial correlation. All analyses controlled for data length and
323 were corrected for multiple comparisons. Between-group main effects were Bonferroni corrected
324 to $p < 0.05$. In order to account for collinearity amongst EEG electrodes and reduce
325 the risk of Type II errors, between-group comparisons of the individual EEG electrodes were
326 instead False Discovery Rate (FDR) corrected to $p < 0.05$.

327

328 **RESULTS**

329 *Electroencephalographic Results*

330 *Slope of the Power Spectrum.* We tested whether the aperiodic spectral slope, averaged
331 across electrodes, differed between the ADHD- and TD groups using ANCOVA, controlling for
332 data segment length. Average slopes were significantly steeper in the ADHD- group ($M=1.67$,
333 $SD=0.27$) compared to the TD group ($M=1.51$, $SD=0.32$; $F_{(1,97)} = 9.58$, $p=0.003$, $\eta^2=0.088$; Fig.
334 2A). This pattern was consistent across all tested electrode pairs, with statistically significant
335 group differences in electrode pairs Cz ($p=0.008$), F3 ($p=0.03$), FCz ($p=0.008$), O1 ($p=0.003$),
336 O2 ($p=0.008$), P4 ($p=0.005$), and Pz ($p=0.008$) after FDR correction (Fig. 2B).

337

338 *Power Spectrum Offset.* Next, we evaluated between-group differences in offset of the
339 power spectrum. A single-factor ANCOVA found that the average offsets were greater for

340 ADHD- (M=1.67, SD=0.43) than for TD (M=1.41, SD=0.48; $F_{(1, 97)}=8.708$, $p=0.004$, $\eta^2=0.082$;
341 Fig. 2C). This pattern was consistent across all electrodes tested with C3 ($p=0.042$), Cz
342 ($p=0.005$), F3 ($p=0.042$), FCz ($p=0.012$), O1 ($p=0.005$), O2 ($p=0.005$), P4 ($p=0.01$), and Pz
343 ($p=0.005$) surviving FDR correction (Fig. 2D).

344

345 *Individual Peak Alpha Frequency.* Individual peak alpha frequencies ranged from 5.75 –
346 11.25 Hz (Fig. 3A). We tested for a difference in the peak alpha frequency between the full TD
347 and ADHD- groups with an ANCOVA, and found no significant difference in average peak
348 alpha between the ADHD- (M=8.43, SD=1.25) and TD (M=8.84, SD=1.03) groups ($F_{(1, 88)}=2.80$,
349 $p=0.098$; $\eta^2=0.031$; Fig. 3B).

350

351 *Narrowband Alpha and Theta.* We estimated the individualized alpha and theta power
352 bands based on the location of each person's peak alpha frequency. Using ANCOVA, we found
353 no significant between-group differences in individualized theta power (Fig. 4A; $F_{(1,97)}=2.15$,
354 $p=0.15$). We did find a significant group-difference in individualized alpha power (Fig. 4B;
355 $F_{(1,97)}=4.38$, $p=0.039$, $\eta^2=0.030$), with greater alpha power in the full ADHD- group (M=0.06,
356 SD=0.018) compared to the TD group (M=0.05, SD=0.018). This pattern was evident across all
357 electrode pairs; group differences at F3 ($p=0.027$), Fz ($p=0.015$), O1 ($p=0.032$), O2 ($p=0.006$),
358 and P4 ($p=0.031$) were statistically significant, although none survived FDR correction (Fig.
359 4C).

360

361 *Theta/Beta Ratio.* Theta/beta ratios have been widely used to compare children with
362 ADHD to TD children. Thus, we evaluated theta/beta ratio in this sample to allow direct
363 comparison to data in the literature and to evaluate the relationship between this established
364 metric and the novel EEG measures reported here. We found no overall difference in theta/beta
365 ratio between the full ADHD- (M=8.66, SD=3.10) and TD groups (M=8.47, SD=2.55;
366 $F_{(1, 97)}=0.371, p=0.544, \eta^2=0.004$; Fig. 5A). We did observe a significant correlation between
367 theta-beta ratio and aperiodic slope, (Fig. 5B; $r=0.293, p=0.003$).

368

369 *Treatment with Stimulant Medications*

370 Because this is the first report of power spectrum slope and offset differences between
371 medication naïve children with or without ADHD, we sought to test whether these differences
372 were modified by exposure to stimulant medication. Specifically, we evaluated power spectrum
373 slope and offset in a subsample of the TD and medication-naïve (ADHD-) groups that were age
374 and gender matched to a sample of 26 children with ADHD currently treated with stimulants,
375 who underwent a 24-hour medication washout prior to completing the study (ADHD+). An
376 ANCOVA found a main effect of group on mean slope ($F_{(2,74)} = 4.76, p=0.011; \eta^2=0.112$; Figure
377 6A). As in the larger sample, the ADHD- group (M=1.71 SD=0.26) had significantly steeper
378 slopes than the TD group (M=1.48, SD=0.36, $p=0.019$ Bonferroni corrected), and also had
379 steeper slopes than the ADHD+ group (M=1.49, SD=0.31, $p=0.044$, Bonferroni corrected). This
380 pattern held across all electrodes (Fig. 6B), with the ADHD- group having significantly steeper
381 slopes than the TD group at Cz ($p=0.024$), FCz ($p=0.019$), O1 ($p=0.019$), P4 ($p=0.019$) and Pz
382 ($p=0.019$), and significantly steeper slopes than the ADHD+ group at Cz ($p=0.019$), FCz
383 ($p=0.019$), O1 ($p=0.019$), P4 ($p=0.019$) and Pz ($p=0.019$) after FDR correction. In contrast, the
384 slopes did not differ between the TD and ADHD+ groups at any electrodes (p 's>0.642).

385 We also found a main effect of group on offset ($F_{(2,74)} = 5.65, p=0.005; \eta^2=0.132$; Fig.
386 6C), with higher average offset in the ADHD- group ($M=1.74$ $SD=0.41$) relative to both the TD
387 group ($M=1.31, SD=0.54, p=0.007$ Bonferroni corrected) and the ADHD+ group ($M=1.38,$
388 $SD=0.52, p=0.038$ Bonferroni corrected). In contrast, there were no significant differences in
389 offset between the ADHD+ and TD groups ($p>0.9$). Amongst individual electrode pairs (Fig.
390 6D), the TD group had significantly lower offset than the ADHD- group for C3 ($p=0.028$), with
391 Cz ($p=0.008$), FCz ($p=0.011$), O1 ($p=0.008$), P4 ($p=0.015$), and Pz ($p=0.008$) withstanding FDR
392 correction. The ADHD+ group had significantly lower offset than the ADHD- group with Cz
393 ($p=0.008$), FCz ($p=0.023$), O1 ($p=0.015$), P4 ($p=0.023$), and Pz ($p=0.015$) withstanding FDR
394 correction. Again, there were no significant differences in offset between the TD and ADHD+
395 groups for any of the electrode pairs ($p's>0.50$).

396

397 **DISCUSSION**

398 By quantifying four distinct features of the EEG power spectrum, including aperiodic slope
399 and offset, peak alpha frequency, and power within individualized alpha and theta bands, we
400 identified a novel neural correlate of ADHD. Moreover, our findings may explain discrepancies
401 in the ADHD literature regarding theta/beta ratios. To summarize, we found that medication
402 naïve children with ADHD had steeper spectral slopes and elevated offsets compared to typically
403 developing children. While this is the first report evaluating spectral slope in children with
404 ADHD, it is consistent with reports of elevated low frequency: high frequency power captured
405 by commonly used theta/beta ratio. While we did not find a significant group difference in
406 theta/beta ratio in this sample, spectral slope positively correlated with theta/beta ratio,
407 suggesting that band-limited theta/beta ratio calculations may inconsistently capture the shift in

408 low relative to high frequency EEG power in ADHD. In contrast, spectral slope considers the
409 full EEG spectrum and may be a better metric as it is not confounded by shifts in aperiodic
410 offset, peak frequencies, or narrow-band power. Together, our findings support the use of
411 spectral slope as a measure of a shift in low relative to high frequency power in ADHD. These
412 results are consistent with another recent study which also found relative band power or power
413 ratios predict ADHD diagnosis with only moderate success, while entropy measures, which
414 capture non-frequency specific global activity, are more successful at predicting ADHD
415 diagnosis (Chen et al. 2019).

416

417 *Stimulant treatment and normalization of aberrant brain activity*

418 As our initial group comparison included only ADHD patients that were medication naïve,
419 we next tested whether our observed electrophysiological group differences were modified by
420 treatment with stimulant medication, which improve behavioral symptoms in children with
421 ADHD, and are the most common medicinal treatment for the disorder (Storebo et al. 2015). We
422 found aperiodic slopes and offsets in stimulant-treated children with ADHD were similar to
423 those of typically developing controls, but were significantly different from the medication naïve
424 ADHD group. These findings are consistent with a growing body of literature showing that
425 stimulant treatment can normalize structural and functional brain abnormalities associated with
426 ADHD (Clarke et al. 2017; Clarke et al. 2003; Nakao et al. 2011; Shaw et al. 2009; Spencer et al.
427 2013). Perhaps most pertinent is a recent study showing a significant reduction in theta/beta ratio
428 in children with ADHD after 1.5 years of stimulant treatment (Isiten et al. 2017); consistent with
429 our results, this normalization persisted even after a 24-hour medication washout period. This
430 finding taken in conjunction with our work supports the idea that flatter slopes in the stimulant-

431 treated and typically developing groups compared with the medication naïve ADHD group could
432 reflect a post-treatment reduction in low relative to high frequency power and a normalization of
433 brain physiology.

434

435 *Relative power across the EEG power spectrum*

436 What underlies an abnormal ratio of low relative to high frequency power in the brain
437 EEG spectrum? Understanding the relative power across frequencies in brain dynamics is an
438 active area of research, and recent studies evaluating the physiological underpinnings of spectral
439 slope suggest that it reflects neural signal to noise ratio (Voytek et al. 2015) and that the spectral
440 slope is an index of the excitatory/inhibitory (E/I) balance of the recorded brain circuits (Gao et
441 al. 2017). Thus, our results may reflect abnormal E/I balance in the cortical circuitry of children
442 with unmedicated ADHD. This interpretation is consistent with observations of altered E/I
443 balance in clinical and preclinical models of ADHD, which have shown reductions in GABA
444 signaling (Edden et al. 2012) and/or increases in glutamate signaling (Courvoisie et al. 2004;
445 Hammerness et al. 2012; Zimmermann et al. 2015). While steeper slope has generally been
446 regarded as reflecting enhanced signal to noise ratio and thus increased GABA or reduced
447 glutamate signaling (Gao et al. 2017; Voytek et al. 2015), perhaps there is a range of cognitively
448 optimal spectral slopes at different developmental stages, with slopes that are either too flat or
449 too steep yielding cognitive impairments. Moreover, similar findings have been noted in a
450 clinical study evaluating 1/f slope in patients with schizophrenia. Despite the association of
451 schizophrenia with reduced GABAergic inhibition in the cortex (Lewis et al. 2005), elevated 1/f
452 slopes during an attention task were found in schizophrenia patients compared to controls, which
453 was proposed to reflect a compensatory increase in GABAergic activity (Peterson et al. 2018).

454 Thus, it is possible that the steeper $1/f$ slopes in medication naïve children with ADHD reflects a
455 compensatory mechanism of some sort. For example, our EEG was collected in a quiet resting
456 state, which may have required substantially more cognitive control in the children with ADHD.
457 However, the fact that the previously medicated ADHD group did not show evidence of such
458 compensation argues against this idea. Still, studies assessing E/I balance using transcranial
459 magnetic stimulation (TMS) have shown that stimulants like methylphenidate, which inhibit
460 reuptake of dopamine and norepinephrine, may rectify E/I balance in ADHD (Buchmann et al.
461 2006; Moll et al. 2000), consistent with the idea that normalization of slope could reflect
462 normalization of E/I balance. Further work is needed to confirm that the effects we observed
463 reflect a stimulant-induced change in E/I balance.

464

465 *Study limitations*

466 Our results indicate a difference in power spectral slope in young children with ADHD
467 compared to typically developing controls, which could represent a transdiagnostic risk factor or
468 an intermediate phenotype, rather than an ADHD specific feature. Previous work has reported
469 variations in spectral slope associated with age (Voytek et al. 2015), and with other clinical
470 diagnoses, including schizophrenia (Peterson et al. 2018). Additionally, evidence that spectral
471 slope may reflect differences in E/I balance (Gao et al. 2017) suggests that spectral slope
472 differences may be present in other disorders with underlying E/I imbalance, such as autism,
473 epilepsy, and alcohol use disorders (reviewed in Fritschy 2008; Gao 2015; Rubenstein and
474 Merzenich 2003; Selten et al. 2018; Wackernah et al. 2014). While the specificity of this
475 difference in spectral slope remains to be tested, our results do suggest that spectral slope more
476 appropriately captures a shift in low relative to high frequency power in ADHD as compared to

477 the theta/beta ratio, which has been frequently reported as an EEG biomarker in children with
478 ADHD (Barry et al. 2003; Loo and Makeig 2012; Monastra et al. 2001; Monastra et al. 1999;
479 Snyder and Hall 2006).

480 We acknowledge certain limitations of this study. First, diagnosis in this study was based
481 on parent report of symptoms, which could be subject to inconsistencies. While we did collect
482 teacher report of symptoms in a subset of participants to confirm diagnostic status, we were
483 unable to do so for all participants. Second, we used a non-traditional EEG data acquisition
484 paradigm; however, this paradigm was chosen due to its superior robustness to the excess
485 movement that occurs in very young study participants (Vuga et al. 2008). Third, in evaluating
486 the chronic impact of stimulant treatment on aperiodic slope and offset, we used a relatively
487 short wash-out period of 24 hours. Previous studies have used a similar washout period (Cole et
488 al. 2008; Isiten et al. 2017; Valera et al. 2010), and given the short half-life of stimulants, even in
489 young children (Wigal et al. 2007), it is unlikely that normalized aperiodic slope and offset in
490 stimulant-treated children are driven entirely by acute drug effects. Still, it is important to note
491 that we did not measure drug levels or compliance with the 24-hour medication wash-out, which
492 was determined by parental report. Thus, we cannot rule out the possibility that acute drug action
493 or stimulant withdrawal could at least partly explain our results.

494

495 *Conclusion*

496 In summary, this study highlights the potential clinical utility of comprehensively quantifying
497 features of the EEG power spectrum. Using this approach, we found that medication naïve
498 children with ADHD had steeper EEG power spectrum slopes and greater EEG power spectrum
499 offsets than typically developing children. Moreover, we show that spectral slope correlates with

500 traditional measures of theta/beta ratio, although theta/beta ratio itself did not differ between
501 groups. This is consistent with spectral slope and offset as a robust and complete measure of
502 relative contributions of low and high frequencies to the overall power spectrum. Interestingly,
503 this difference was not apparent in stimulant-treated children with ADHD, despite a 24-hour
504 medication washout. Thus, spectral slope may reflect pathology in the brains of children with
505 ADHD that is normalized by stimulant medication. Future studies should evaluate whether these
506 group differences in spectral slope and offset can be replicated in older children and adults with
507 ADHD, determine whether there are interaction effects of age and gender, and assess
508 normalization of slope and offset after stimulant treatment using random assignment.

509
510
511
512
513
514

515 REFERENCES

516 **Achenbach TM.** Child Behavior Checklist and related instruments. In: *The use of psychological*
517 *testing for treatment planning and outcome assessment.* Hillsdale, NJ, US: Lawrence Erlbaum
518 Associates, Inc, 1994, p. 517-549.

519 **Arns M, Conners CK, and Kraemer HC.** A decade of EEG Theta/Beta Ratio Research in
520 ADHD: a meta-analysis. *J Atten Disord* 17: 374-383, 2013.

521 **Aurlen H, Gjerde IO, Aarseth JH, Eldøen G, Karlsen B, Skeidsvoll H, and Gilhus NE.**
522 EEG background activity described by a large computerized database. *Clinical Neurophysiology*
523 115: 665-673, 2004.

524 **Barry RJ, Clarke AR, and Johnstone SJ.** A review of electrophysiology in attention-
525 deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. *Clinical*
526 *Neurophysiology* 114: 171-183, 2003.

527 **Basar E, Basar-Eroglu C, Karakas S, and Schurmann M.** Are cognitive processes manifested
528 in event-related gamma, alpha, theta and delta oscillations in the EEG? *Neuroscience letters* 259:
529 165-168, 1999.

530 **Basar E, Basar-Eroglu C, Karakas S, and Schurmann M.** Gamma, alpha, delta, and theta
531 oscillations govern cognitive processes. *Int J Psychophysiol* 39: 241-248, 2001.

532 **Bruchmuller K, Margraf J, and Schneider S.** Is ADHD Diagnosed in Accord With Diagnostic
533 Criteria? Overdiagnosis and Influence of Client Gender on Diagnosis. *Journal of Consulting and*
534 *Clinical Psychology* 80: 128-138, 2012.

535 **Buchmann J, Gierow W, Weber S, Hoepfner J, Klauer T, Wittstock M, Benecke R,**
536 **Haessler F, and Wolters A.** Modulation of transcallosally mediated motor inhibition in children
537 with attention deficit hyperactivity disorder (ADHD) by medication with methylphenidate
538 (MPH). *Neuroscience letters* 405: 14-18, 2006.

539 **Chen H, Chen W, Song Y, Sun L, and Li X.** EEG characteristics of children with attention-
540 deficit/hyperactivity disorder. *Neuroscience* 406: 444-456, 2019.

541 **Clarke AR, Barry RJ, Baker IE, McCarthy R, and Selikowitz M.** An Investigation of
542 Stimulant Effects on the EEG of Children With Attention-Deficit/Hyperactivity Disorder. *Clin*
543 *EEG Neurosci* 48: 235-242, 2017.

544 **Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Brown CR, and Croft RJ.** Effects of
545 stimulant medications on the EEG of children with Attention-Deficit/Hyperactivity Disorder
546 Predominantly Inattentive type. *Int J Psychophysiol* 47: 129-137, 2003.

547 **Cole WR, Mostofsky SH, Larson JC, Denckla MB, and Mahone EM.** Age-related changes in
548 motor subtle signs among girls and boys with ADHD. *Neurology* 71: 1514-1520, 2008.

549 **Conners C.** Conners Rating Scales-Revised. North Tonawanda, NY: Multihealth Systems, 2001.

550 **Courvoisie H, Hooper SR, Fine C, Kwock L, and Castillo M.** Neurometabolic functioning and
551 neuropsychological correlates in children with ADHD-H: preliminary findings. *The Journal of*
552 *neuropsychiatry and clinical neurosciences* 16: 63-69, 2004.

553 **Delorme A, and Makeig S.** EEGLAB: an open source toolbox for analysis of single-trial EEG
554 dynamics including independent component analysis. *Journal of neuroscience methods* 134: 9-
555 21, 2004.

556 **Doppelmayr M, Klimesch W, Pachinger T, and Ripper B.** Individual differences in brain
557 dynamics: important implications for the calculation of event-related band power. *Biological*
558 *cybernetics* 79: 49-57, 1998.

559 **Edden RA, Crocetti D, Zhu H, Gilbert DL, and Mostofsky SH.** Reduced GABA
560 concentration in attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry* 69: 750-753, 2012.

561 **Epstein HT.** EEG developmental stages. *Developmental psychobiology* 13: 629-631, 1980.

562 **Fernandez A, Maestu F, Amo C, Gil P, Fehr T, Wienbruch C, Rockstroh B, Elbert T, and**
563 **Ortiz T.** Focal temporoparietal slow activity in Alzheimer's disease revealed by
564 magnetoencephalography. *Biol Psychiatry* 52: 764-770, 2002.

565 **Fritschy J-M.** Epilepsy, E/I Balance and GABA(A) Receptor Plasticity. *Frontiers in molecular*
566 *neuroscience* 1: 5-5, 2008.

567 **Gao R.** Interpreting the electrophysiological power spectrum. *J Neurophysiol* 115: 628-630,
568 2016.

569 **Gao R, Penzes, P.** Common mechanisms of excitatory inhibitory imbalance in schizophrenia
570 and autism spectrum disorders. *Current Molecular Medicine* 15: 146-167, 2015.

571 **Gao R, Peterson EJ, and Voytek B.** Inferring synaptic excitation/inhibition balance from field
572 potentials. *Neuroimage* 158: 70-78, 2017.

573 **Gasser T, Bacher P, and Mocks J.** Transformations towards the normal distribution of broad
574 band spectral parameters of the EEG. *Electroencephalography and clinical neurophysiology* 53:
575 119-124, 1982.

576 **Grandy TH, Werkle-Bergner M, Chicherio C, Schmiedek F, Lovden M, and Lindenberger**
577 **U.** Peak individual alpha frequency qualifies as a stable neurophysiological trait marker in
578 healthy younger and older adults. *Psychophysiology* 50: 570-582, 2013.

579 **Haller M, Donoghue T, Peterson E, Varma P, Sebastian P, Gao R, Noto T, Knight RT,**
580 **Shestyk A, and Voytek B.** Parameterizing neural power spectra. *BioRxiv* 2018.

581 **Hammerness P, Biederman J, Petty C, Henin A, and Moore CM.** Brain biochemical effects
582 of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit
583 hyperactivity disorder: a controlled pilot study. *CNS Neurosci Ther* 18: 34-40, 2012.

584 **He BJ.** Scale-free brain activity: past, present, and future. *Trends Cogn Sci* 18: 480-487, 2014.

585 **Hsieh L-T, and Ranganath C.** Frontal midline theta oscillations during working memory
586 maintenance and episodic encoding and retrieval. *NeuroImage* 85: 721-729, 2014.

587 **Isiten HN, Cebi M, Sutubasi Kaya B, Metin B, and Tarhan N.** Medication Effects on EEG
588 Biomarkers in Attention-Deficit/Hyperactivity Disorder. *Clin EEG Neurosci* 48: 246-250, 2017.

589 **Kappenman ES, and Luck SJ.** The effects of electrode impedance on data quality and
590 statistical significance in ERP recordings. *Psychophysiology* 47: 888-904, 2010.

591 **Klimesch W.** EEG alpha and theta oscillations reflect cognitive and memory performance: a
592 review and analysis. *Brain research Brain research reviews* 29: 169-195, 1999.

593 **Lewis DA, Hashimoto T, and Volk DW.** Cortical inhibitory neurons and schizophrenia. *Nat*
594 *Rev Neurosci* 6: 312-324, 2005.

595 **Liu Q, Balsters JH, Baechinger M, van der Groen O, Wenderoth N, and Mantini D.**
596 Estimating a neutral reference for electroencephalographic recordings: the importance of using a
597 high-density montage and a realistic head model. *Journal of neural engineering* 12: 056012,
598 2015.

599 **Loe IM, and Feldman HM.** Academic and educational outcomes of children with ADHD.
600 *Ambul Pediatr* 7: 82-90, 2007.

601 **Loo SK, and Makeig S.** Clinical utility of EEG in attention-deficit/hyperactivity disorder: a
602 research update. *Neurotherapeutics* 9: 569-587, 2012.

603 **Luu P, and Ferree T.** Determination of the HydroCel Geodesic Sensor Nets' Average Electrode
604 Positions and Their 10-10 International Equivalents. 2005.

605 **Makeig S, Westerfield M, Jung TP, Enghoff S, Townsend J, Courchesne E, and Sejnowski**
606 **TJ.** Dynamic brain sources of visual evoked responses. *Science (New York, NY)* 295: 690-694,
607 2002.

608 **Manning JR, Jacobs J, Fried I, and Kahana MJ.** Broadband shifts in local field potential
609 power spectra are correlated with single-neuron spiking in humans. *J Neurosci* 29: 13613-13620,
610 2009.

611 **Marshall PJ, Bar-Haim Y, and Fox NA.** Development of the EEG from 5 months to 4 years of
612 age. *Clin Neurophysiol* 113: 1199-1208, 2002.

613 **Merten EC, Cwik JC, Margraf J, and Schneider S.** Overdiagnosis of mental disorders in
614 children and adolescents (in developed countries). *Child Adolesc Psychiatry Ment Health* 11: 5,
615 2017.

616 **Moll GH, Heinrich H, Trott G, Wirth S, and Rothenberger A.** Deficient intracortical
617 inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by
618 methylphenidate. *Neuroscience letters* 284: 121-125, 2000.

619 **Monastra VJ, Lubar JF, and Linden M.** The development of a quantitative
620 electroencephalographic scanning process for attention deficit-hyperactivity disorder: reliability
621 and validity studies. *Neuropsychology* 15: 136-144, 2001.

622 **Monastra VJ, Lubar JF, Linden M, VanDeusen P, Green G, Wing W, Phillips A, and**
623 **Fenger TN.** Assessing attention deficit hyperactivity disorder via quantitative
624 electroencephalography: an initial validation study. *Neuropsychology* 13: 424-433, 1999.

625 **Nakao T, Radua J, Rubia K, and Mataix-Cols D.** Gray matter volume abnormalities in
626 ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. *The*
627 *American journal of psychiatry* 168: 1154-1163, 2011.

628 **Onton J, and Makeig S.** Information-based modeling of event-related brain dynamics. *Progress*
629 *in brain research* 159: 99-120, 2006.

630 **Peterson EJ, Rosen BQ, Campbell AM, Belger A, and Voytek B.** 1/f neural noise is a better
631 predictor of schizophrenia than neural oscillations. *bioRxiv* 113449, 2018.

632 **Podvalny E, Noy N, Harel M, Bickel S, Chechik G, Schroeder CE, Mehta AD, Tsodyks M,**
633 **and Malach R.** A unifying principle underlying the extracellular field potential spectral
634 responses in the human cortex. *J Neurophysiol* 114: 505-519, 2015.

635 **Polanczyk GV, de Lima MS, Horta BL, Biederman J, and Rohde LA.** The worldwide
636 prevalence of ADHD: a systematic review and metaregression analysis. *The American journal of*
637 *psychiatry* 164: 942-948, 2007.

638 **Polanczyk GV, Willcutt EG, Salum GA, Kieling C, and Rohde LA.** ADHD prevalence
639 estimates across three decades: an updated systematic review and meta-regression analysis. *Int J*
640 *Epidemiol* 43: 434-442, 2014.

641 **Rubenstein JL, and Merzenich MM.** Model of autism: increased ratio of excitation/inhibition
642 in key neural systems. *Genes, brain, and behavior* 2: 255-267, 2003.

643 **Saad JF, Kohn MR, Clarke S, Lagopoulos J, and Hermens DF.** Is the Theta/Beta EEG
644 Marker for ADHD Inherently Flawed? *J Atten Disord* 22: 815-826, 2018.

645 **Selten M, van Bokhoven H, and Nadif Kasri N.** Inhibitory control of the excitatory/inhibitory
646 balance in psychiatric disorders. *F1000Res* 7: 23, 2018.

647 **Shaffer D, Fisher P, Lucas CP, Dulcan MK, and Schwab-Stone ME.** NIMH Diagnostic
648 Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from
649 previous versions, and reliability of some common diagnoses. *J Am Acad Child Adolesc*
650 *Psychiatry* 39: 28-38, 2000.

651 **Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, Clasen LS, Evans AC, and**
652 **Rapoport JL.** Psychostimulant treatment and the developing cortex in attention deficit
653 hyperactivity disorder. *The American journal of psychiatry* 166: 58-63, 2009.

654 **Snyder SM, and Hall JR.** A meta-analysis of quantitative EEG power associated with attention-
655 deficit hyperactivity disorder. *Journal of clinical neurophysiology : official publication of the*
656 *American Electroencephalographic Society* 23: 440-455, 2006.

657 **Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, and**
658 **Biederman J.** Effect of psychostimulants on brain structure and function in ADHD: a qualitative
659 literature review of magnetic resonance imaging-based neuroimaging studies. *J Clin Psychiatry*
660 74: 902-917, 2013.

661 **Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, Nilausen**
662 **TD, Magnusson FL, Zwi M, Gillies D, Rosendal S, Groth C, Rasmussen KB, Gauci D,**
663 **Kirubakaran R, Forsbol B, Simonsen E, and Gluud C.** Methylphenidate for attention-
664 deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with
665 meta-analyses and trial sequential analyses of randomised clinical trials. *Bmj* 351: h5203, 2015.

666 **Swanson JM.** The SNAP-IV teacher and parent rating scale. 2011.

667 **Thomas R, Sanders S, Doust J, Beller E, and Glasziou P.** Prevalence of Attention-
668 Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. *Pediatrics* 135: e994-
669 e1001, 2015.

670 **Valera EM, Spencer RM, Zeffiro TA, Makris N, Spencer TJ, Faraone SV, Biederman J,**
671 **and Seidman LJ.** Neural substrates of impaired sensorimotor timing in adult attention-
672 deficit/hyperactivity disorder. *Biol Psychiatry* 68: 359-367, 2010.

673 **Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, Perou R,**
674 **and Blumberg SJ.** Trends in the parent-report of health care provider-diagnosed and medicated
675 attention-deficit/hyperactivity disorder: United States, 2003-2011. *J Am Acad Child Adolesc*
676 *Psychiatry* 53: 34-46 e32, 2014.

677 **Voytek B, Kramer MA, Case J, Lepage KQ, Tempesta ZR, Knight RT, and Gazzaley A.**
678 Age-Related Changes in 1/f Neural Electrophysiological Noise. *J Neurosci* 35: 13257-13265,
679 2015.

680 **Vuga M, Fox NA, Cohn JF, Kovacs M, and George CJ.** Long-term stability of
681 electroencephalographic asymmetry and power in 3 to 9 year-old children. *Int J Psychophysiol*
682 *67: 70-77, 2008.*

683 **Wackernah RC, Minnick MJ, and Clapp P.** Alcohol use disorder: pathophysiology, effects,
684 and pharmacologic options for treatment. *Subst Abuse Rehabil* 5: 1-12, 2014.

685 **Wehmeier PM, Schacht A, and Barkley RA.** Social and emotional impairment in children and
686 adolescents with ADHD and the impact on quality of life. *J Adolesc Health* 46: 209-217, 2010.

687 **Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, Wigal T, Kapelinski A,**
688 **Martinez J, Modi NB, Stehli A, and Swanson J.** Pharmacokinetics of methylphenidate in
689 preschoolers with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 17:
690 153-164, 2007.

691 **Wilens TE, Martelon M, Joshi G, Bateman C, Fried R, Petty C, and Biederman J.** Does
692 ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD.
693 *J Am Acad Child Adolesc Psychiatry* 50: 543-553, 2011.

694 **Winkler I, Brandl S, Horn F, Waldburger E, Allefeld C, and Tangermann M.** Robust
695 artifactual independent component classification for BCI practitioners. *Journal of neural*
696 *engineering* 11: 035013, 2014.

697 **Winkler I, Debener S, Muller KR, and Tangermann M.** On the influence of high-pass
698 filtering on ICA-based artifact reduction in EEG-ERP. *Conference proceedings : Annual*
699 *International Conference of the IEEE Engineering in Medicine and Biology Society IEEE*
700 *Engineering in Medicine and Biology Society Annual Conference 2015: 4101-4105, 2015.*

701 **Winkler I, Haufe S, and Tangermann M.** Automatic classification of artifactual ICA-
702 components for artifact removal in EEG signals. *Behavioral and brain functions : BBF* 7: 30,
703 2011.

704 **Xu G, Strathearn L, Liu B, Yang B, and Bao W.** Twenty-Year Trends in Diagnosed
705 Attention-Deficit/Hyperactivity Disorder Among US Children and Adolescents, 1997-2016.
706 *JAMA Netw Open* 1: e181471, 2018.

707 **Zimmermann AM, Jene T, Wolf M, Gorlich A, Gurniak CB, Sassoe-Pognetto M, Witke W,**
708 **Friauf E, and Rust MB.** Attention-Deficit/Hyperactivity Disorder-like Phenotype in a Mouse
709 Model with Impaired Actin Dynamics. *Biol Psychiatry* 78: 95-106, 2015.

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724 **FIGURE LEGENDS**

725 **Figure 1.** Schematic of the four components of the electrophysiological power spectrum. (A)
726 Low (solid) and high (dashed) power in the alpha range. (B) Low (dashed) and high (solid) peak
727 alpha frequency. (C) Flat (solid) and steep (dashed) slopes. (D) Low (solid) and high (dashed)
728 offsets.

729

730 **Figure 2.** Comparisons of slope (A-B) and offset (C-D) in the full TD (black/solid) and ADHD-
731 (white/dashed) samples. Error bars reflect +/- SD. (A) ADHD- has steeper slopes compared to
732 TD when averaging across participants and electrodes. (B) Slopes were steeper in ADHD- for all
733 electrodes tested, with asterisks denoting statistical significance after FDR correction. (C)
734 ADHD- has greater offset compared to TD when averaging across participants and electrodes.
735 (D) This pattern holds when considering electrodes individually, with asterisks denoting
736 statistical significance after FDR correction.

737 **Figure 3.** Individual alpha frequency as determined by visual inspection of the power spectrums
738 for the sample of TD (black) and ADHD- (white) participants. (A) Cumulative frequency plot
739 showing the proportion of peaks which fall at various points across the alpha range. (B) Peak
740 alpha frequency group averages showed no significant differences between TD and ADHD-.
741 Error bars reflect +/- SD.

742 **Figure 4.** Theta (A) and alpha (B-C) power for the full sample of TD (black/solid) and ADHD-
743 (white/dashed) participants calculated using individualized frequency bands based on peak alpha.
744 Error bars reflect +/- SD. (A) There is no significant group difference in theta power. (B)
745 ADHD- has elevated alpha power compared to TD. (C) While ADHD- had higher alpha power
746 than TD in all tested electrodes, this group difference was not significant for any individual
747 electrode pairs after FDR correction.

748 **Figure 5.** Theta/beta ratio for the full sample of TD (black) and ADHD- (white) participants.
749 (A) There was no significant group difference in theta/beta ratio between TD and ADHD-. Error
750 bars reflect +/- SD. (B) Theta/beta ratio was significantly correlated with slope.

751 **Figure 6.** Slope (A-B) and offset (C-D) for the ADHD+ group (gray), and the age- and gender-
752 matched TD (black) and ADHD- (white/dashed) subgroups. Error bars reflect +/- SD. Asterisks
753 denotes significant difference between TD and ADHD-, while pound signs denote significant
754 differences between ADHD- and ADHD+. (A) ADHD- has steeper slopes compared to both TD
755 and ADHD+ when averaging across participants and electrodes. (B) Slopes were steeper in
756 ADHD- for all electrodes tested, with symbols denoting statistical significance after FDR
757 correction. (C) ADHD- has greater offset compared to TD and ADHD+ when averaging across
758 participants and electrodes. (D) This pattern holds when considering electrodes individually,
759 with symbols denoting statistical significance after FDR correction.

760

761

762 TABLES

763 **Table 1.** Group demographics for the full ADHD- and TD samples, as well as the subgroups
 764 selected for age and gender matching with the ADHD+ group.

	<i>ADHD-</i> (<i>n=50</i>)	<i>TD</i> (<i>n=50</i>)	<i>ADHD-</i> (<i>n=26</i>)	<i>ADHD+</i> (<i>n=26</i>)	<i>TD</i> (<i>n=26</i>)
	% (n)	% (n)	% (n)	% (n)	% (n)
Female	28 (14)	28 (14)	23.1 (6)	23.1 (6)	23.1 (6)
Handedness (R)	86 (43)	90 (45)	84.6 (22)	76.9 (20)	96.2 (25)
Race					
<i>White</i>	66 (33)	62 (31)	69.2 (18)	88.5 (23)	73.1 (19)
<i>Black/African American</i>	12 (6)	12 (6)	11.5 (3)	3.8 (1)	11.5 (3)
<i>Asian</i>	0 (0)	6 (3)	0 (0)	0 (0)	3.8 (1)
<i>Other/Multiracial</i>	18 (9)	20 (10)	15.5 (4)	7.7 (2)	11.5 (3)
Hispanic/Latino	18 (9)	6 (3)	23.1 (6)	15.4 (4)	7.7 (2)
	<i>M ± SD</i>	<i>M ± SD</i>	<i>M ± SD</i>	<i>M ± SD</i>	<i>M ± SD</i>
Age (months)	67.70 ± 14.66	67.76 ± 14.76	74.50 ± 10.38	74.88 ± 9.71	74.81 ± 10.12

765 Values presented as a percent of total group, with the raw number in parenthesis. Age is
 766 expressed as mean ± standard deviation. ADHD-, medication naive ADHD group; TD, typically
 767 developing control group; ADHD+, stimulant treated ADHD group after 24-hour medication
 768 washout.

769

770

771

772

773

774

775

776

777

778

779

780 **Table 2.** Average ADHD symptoms for the complete ADHD- and TD samples.

	ADHD- vs TD 781			
	<i>ADHD-</i> <i>(n=50)</i>	<i>TD (n=50)</i>	Group Differences	
	<i>M ± SD</i> <i>(N)</i>	<i>M ± SD</i> <i>(N)</i>	<i>t</i>	<i>p</i>
<i>DISC Symptoms (0-23)</i>	16.31 ± 4.10 (48)	3.78 ± 3.84 (45)	-15.2	<0.001*
<i>CBCL Attention Problems t-score</i>	66.88 ± 6.97 (50)	52.00 ± 3.47 (49)	-13.41	<0.001*
<i>SNAP-IV (0-9)</i>				
<i>Inattentiveness</i>	5.47 ± 2.53 (47)	0.69 ± 1.13 (48)	-11.94	<0.001*
<i>Hyperactivity</i>	6.21 ± 2.56 (48)	1.25 ± 1.71 (48)	-11.17	<0.001*
<i>Teachers Conners</i>				
<i>Inattention t-score</i>	61.25 ± 11.77 (16)	46.69 ± 8.53 (13)	-3.73	0.001*
<i>Hyperactive t-score</i>	74.69 ± 12.97 (16)	53.64 ± 16.93 (11)	-3.66	0.001*
<i>TRF ADHD t-score</i>	58.83 ± 11.91 (6)	53.25 ± 4.30 (8)	-1.237	0.24

782 Values are presented as mean ± standard deviation. The number of participants with scores for
783 each measure is listed in parenthesis. As expected, the ADHD- (medication naïve ADHD) group
784 had significantly more ADHD symptoms compared to TD (typically developing) on all measures
785 with the exception of the TRF (Teacher Report Form), which was completed in a small number
786 of total cases. DISC, the Diagnostic Structured Interview Schedule– young child version; CBCL,
787 Child Behavior Checklist; SNAP-IV, Swanson Nolan and Pelham Checklist.

788

789

790

791

792

793

794


795 **Table 3.** Average ADHD symptoms for the ADHD+ group, and the TD and ADHD- subgroups.





	ADHD- vs ADHD+ vs TD					
	ADHD- (n=26)	ADHD+ (n=26)	TD (n=26)	Group Differences		
	Mean ± SD (N)	M ± SD (N)	M ± SD (N)	ADHD- vs. ADHD+	ADHD- vs TD	ADHD+ vs TD
DISC Symptoms (0-23)	17.27 ± 3.08 (26)	18.31 ± 3.67 (26)	3.88 ± 3.70 (25)	0.862	<0.001*	<0.001*
CBCL Attention Problems t-score	67.31 ± 6.45 (26)	68.78 ± 5.74 (23)	52.04 ± 3.87 (26)	>0.99	<0.001*	<0.001*
SNAP-IV (0-9)						
<i>Inattentiveness</i>	5.67 ± 2.24 (24)	7.46 ± 2.11 (24)	0.46 ± 1.14 (24)	0.005*	<0.001*	<0.001*
<i>Hyperactivity</i>	6.0 ± 2.71	7.54 ± 2.23	0.75 ± 1.29	0.045*	<0.001*	<0.001*

796 Values are presented as mean ± standard deviation. The number of participants with scores for
 797 each measure is listed in parenthesis. The ADHD+ (stimulant treated ADHD after medication
 798 washout) and ADHD- (medication naïve ADHD) groups have significantly more symptoms on
 799 all parent report measures as compared to TD (typically developing). However, ADHD-, but not
 800 ADHD+, had significantly more symptoms than TD on teacher report measures, likely due to
 801 effects of medication during school hours. Abbreviations as reported in Table 2.


	(25)	(24)	(24)			
Teachers Conners						
<i>Inattention t-score</i>	59.27 ± 11.73 (11)	53.92 ± 8.39 (12)	44.82 ± 5.33 (11)	0.473	0.002*	0.059
<i>Hyperactive t-score</i>	74.47 ± 13.02 (11)	62.08 ± 16.04 (12)	51.00 ± 12.85 (9)	0.137	0.003*	0.261
TRF ADHD t-score	50 (1)	60.2 ± 7.92 (5)	54.0 ± 4.95 (5)			0.176

802











A



B











Table 1. Group demographics for the full ADHD- and TD samples, as well as the subgroups selected for age and gender matching with the ADHD+ group.

	<i>ADHD-</i> (<i>n=50</i>)	<i>TD</i> (<i>n=50</i>)	<i>ADHD-</i> (<i>n=26</i>)	<i>ADHD+</i> (<i>n=26</i>)	<i>TD</i> (<i>n=26</i>)
	% (n)	% (n)	% (n)	% (n)	% (n)
Female	28 (14)	28 (14)	23.1 (6)	23.1 (6)	23.1 (6)
Handedness (R)	86 (43)	90 (45)	84.6 (22)	76.9 (20)	96.2 (25)
Race					
<i>White</i>	66 (33)	62 (31)	69.2 (18)	88.5 (23)	73.1 (19)
<i>Black/African American</i>	12 (6)	12 (6)	11.5 (3)	3.8 (1)	11.5 (3)
<i>Asian</i>	0 (0)	6 (3)	0 (0)	0 (0)	3.8 (1)
<i>Other/Multiracial</i>	18 (9)	20 (10)	15.5 (4)	7.7 (2)	11.5 (3)
Hispanic/Latino	18 (9)	6 (3)	23.1 (6)	15.4 (4)	7.7 (2)
	<i>M ± SD</i>	<i>M ± SD</i>	<i>M ± SD</i>	<i>M ± SD</i>	<i>M ± SD</i>
Age (months)	67.70 ± 14.66	67.76 ± 14.76	74.50 ± 10.38	74.88 ± 9.71	74.81 ± 10.12

Values presented as a percent of total group, with the raw number in parenthesis. Age is expressed as mean ± standard deviation. ADHD-, medication naive ADHD group; TD, typically developing control group; ADHD+, stimulant treated ADHD group after 24-hour medication washout.

Table 2. Average ADHD symptoms for the complete ADHD- and TD samples.

	ADHD- vs TD			
	ADHD- (n=50)	TD (n=50)	Group Differences	
	<i>M</i> ± <i>SD</i> (<i>N</i>)	<i>M</i> ± <i>SD</i> (<i>N</i>)	<i>t</i>	<i>p</i>
DISC Symptoms (0-23)	16.31 ± 4.10 (48)	3.78 ± 3.84 (45)	-15.2	<0.001*
CBCL Attention Problems t-score	66.88 ± 6.97 (50)	52.00 ± 3.47 (49)	-13.41	<0.001*
SNAP-IV (0-9)				
<i>Inattentiveness</i>	5.47 ± 2.53 (47)	0.69 ± 1.13 (48)	-11.94	<0.001*
<i>Hyperactivity</i>	6.21 ± 2.56 (48)	1.25 ± 1.71 (48)	-11.17	<0.001*
Teachers Conners				
<i>Inattention t-score</i>	61.25 ± 11.77 (16)	46.69 ± 8.53 (13)	-3.73	0.001*
<i>Hyperactive t-score</i>	74.69 ± 12.97 (16)	53.64 ± 16.93 (11)	-3.66	0.001*
TRF ADHD t-score	58.83 ± 11.91 (6)	53.25 ± 4.30 (8)	-1.237	0.24

Values are presented as mean ± standard deviation. The number of participants with scores for each measure is listed in parenthesis. As expected, the ADHD- (medication naïve ADHD) group had significantly more ADHD symptoms compared to TD (typically developing) on all measures with the exception of the TRF (Teacher Report Form), which was completed in a small number of total cases. DISC, the Diagnostic Structured Interview Schedule– young child version; CBCL, Child Behavior Checklist; SNAP-IV, Swanson Nolan and Pelham Checklist.

Table 3. Average ADHD symptoms for the ADHD+ group, and the TD and ADHD- subgroups.

	ADHD- vs ADHD+ vs TD					
	ADHD- (n=26)	ADHD+ (n=26)	TD (n=26)	Group Differences		
	Mean ± SD (N)	M ± SD (N)	M ± SD (N)	ADHD- vs. ADHD+	ADHD- vs TD	ADHD+ vs TD
DISC Symptoms (0-23)	17.27 ± 3.08 (26)	18.31 ± 3.67 (26)	3.88 ± 3.70 (25)	0.862	<0.001*	<0.001*
CBCL Attention Problems t-score	67.31 ± 6.45 (26)	68.78 ± 5.74 (23)	52.04 ± 3.87 (26)	>0.99	<0.001*	<0.001*
SNAP-IV (0-9)						
<i>Inattentiveness</i>	5.67 ± 2.24 (24)	7.46 ± 2.11 (24)	0.46 ± 1.14 (24)	0.005*	<0.001*	<0.001*
<i>Hyperactivity</i>	6.0 ± 2.71 (25)	7.54 ± 2.23 (24)	0.75 ± 1.29 (24)	0.045*	<0.001*	<0.001*
Teachers Connors						
<i>Inattention t-score</i>	59.27 ± 11.73 (11)	53.92 ± 8.39 (12)	44.82 ± 5.33 (11)	0.473	0.002*	0.059
<i>Hyperactive t-score</i>	74.47 ± 13.02 (11)	62.08 ± 16.04 (12)	51.00 ± 12.85 (9)	0.137	0.003*	0.261
TRF ADHD t-score	50 (1)	60.2 ± 7.92 (5)	54.0 ± 4.95 (5)			0.176

Values are presented as mean ± standard deviation. The number of participants with scores for each measure is listed in parenthesis. The ADHD+ (stimulant treated ADHD after medication washout) and ADHD- (medication naïve ADHD) groups have significantly more symptoms on all parent report measures as compared to TD (typically developing). However, ADHD-, but not ADHD+, had significantly more symptoms than TD on teacher report measures, likely due to effects of medication during school hours. Abbreviations as reported in Table 2.